Microdosing LSD as a therapeutic for neuroinflammation associated with Alzheimer’s
2020-08-13 2020-08-13 4:30Microdosing LSD as a therapeutic for neuroinflammation associated with Alzheimer’s
Microdosing LSD as a therapeutic for neuroinflammation associated with Alzheimer’s
As someone who lost a father to Alzheimer’s disease, these findings paving the way to further study are exciting.
Conclusions: Our results suggest safety and tolerability of orally administered 5 μg, 10 μg, and 20 μg LSD every fourth day over a 21-day period and support further clinical development of LSD for the treatment and prevention of Alzheimer’s disease (AD).
https://pubmed.ncbi.nlm.nih.gov/31853557/
